The market for pyelonephritis treatments presents opportunities in novel drug development, emphasizing advanced ESBL coverage and efficacy under acidic conditions. Key players include Wockhardt and ...
Levofloxacin-induced myopathy is a relatively under-recognized adverse effect. Here, we present a case of myopathy affecting ...
The FDA approved nerandomilast (Jascayd) tablets for idiopathic pulmonary fibrosis (IPF), the first new product for the progressive lung condition in over a decade, the agency announced on Tuesday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback